Skip to Main Content

Paper Details

Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
N Engl J Med
1
2023
Author NameAffiliation
Roy S HerbstYale Cancer Center
  • 1 - 1

Datasets

Release 1.2